# OnCo record cancer-associated-vte-treatment (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/cancer-associated-vte-treatment/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "cancer-associated-vte-treatment" ;
  schema:name "Anticoagulation for a blood clot in a person with cancer: choice of drug, duration and special situations"@en ;
  schema:alternateName "cancer-associated thrombosis treatment"@en, "CAT treatment"@en, "DVT in cancer"@en, "pulmonary embolism in cancer"@en, "DOAC or LMWH in cancer"@en, "apixaban for cancer clot"@en, "dalteparin"@en, "anticoagulation duration cancer"@en ;
  schema:description "Clots in a leg vein or the lungs are common in cancer. They are treated with blood thinners, either daily injections (low-molecular-weight heparin) or tablets (such as apixaban, rivaroxaban or edoxaban), usually for at least six months and often while the cancer is active. Tablets suit most people, but injections may be safer with some stomach, bowel or bladder cancers and some cancer drugs."@en ;
  schema:url <https://onco.cc/protocols/cancer-associated-vte-treatment/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:related <https://onco.cc/protocols/catheter-related-thrombosis-in-cancer/> ;
  onco:technologies <https://onco.cc/technologies/cancer-associated-thrombosis/> ;
  onco:terms <https://onco.cc/terms/vte/>, <https://onco.cc/terms/thrombocytopenia/> .